Navigation Links
UCLA scientists uncover mechanism for melanoma drug resistance
Date:3/6/2012

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it.

Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene.

By examining the part of the melanoma genome that encodes proteins, called the exome, Jonsson Cancer Center scientists discovered that in some patients with BRAF-mutated metastatic melanoma, the mutated BRAF gene driving the cancer becomes amplified as the cancer develops resistance to a BRAF inhibitor. Quite simply, by increasing the copies of the mutated BRAF gene, the melanoma is trying to over produce the drug target protein and outnumber the inhibitor. The findings may lead to alternative ways of preventing or treating resistant melanomas.

"Understanding and solving the problem of how cancer gets around targeted drugs is arguably one of the highest priorities in modern day cancer medicine. In this study, we found that in some patients, the cancer simply makes more of the target, the mutated BRAF gene, so that the drug dose becomes too weak to fight the cancer," said study senior author Dr. Roger Lo, an assistant professor of dermatology and molecular and medical pharmacology and a Jonsson Cancer Center scientist. "If you think of the mutation as a right hand and the BRAF inhibitor as a left hand and the two clasp to be effective, there's clearly an optimal radio to ensure the mutated gene is fully inhibited. Here, we get more of the drug target, which has the same effect as dropping the drug level."

The one-year study is published March 6, 2012, in the peer-reviewed journal Nature Communications.

About 50 percent of patients with metastatic melanoma, or 4,000 people a year, have the BRAF mutation and can be treated with Zelboraf, two pills taken twice a day. Zelboraf was approved by the U.S. Food and Drug Administration for use in metastatic melanoma in August of 2011. Many other common human cancers, including colon, thyroid and lung, also harbor BRAF-mutated subsets, Lo said.

Oncologists cannot give more Zelboraf to these patients to combat the increased number of mutated BRAF genes because the dose approved by the FDA is the maximum tolerated dose, Lo said. However, Zelboraf could perhaps be given with inhibitors of other cell signaling pathways in metastatic melanoma to try and stop patients from becoming resistant.

Lo and his team examined samples of 20 patients for this study, taking their normal tissue, their tumor tissue before treatment with Zelboraf and a sample when the cancer had responded earlier but subsequently became resistant. Using high-throughput DNA sequencing technology, the scientists examined the entire cancer exome to see what changes were occurring that may point to resistant mechanisms. Lo found that five of the 20 patients showed increased copies of the mutated BRAF gene. Cell lines developed from melanoma patients also showed pathways downstream of the amplified gene that could be blocked with inhibitors to fight resistance.

"For the first time, we were able to see in actual patient tissue samples how the cancer gets around this drug by altering the target," Lo said. "It appears that the drug target is not only mutated and hyper-activated, but it's also massively over-produced in some cases of clinical relapse."

Lo said there's an experimental drug that also inhibits mutated BRAF which may be effective against this form of melanoma at a dose that does not result in substantial side effects. In that case, an oncologist might have room to increase the drug dose once a relapse driven by BRAF amplification is encountered in the clinic.

Scientists so far have discovered five mechanisms of BRAF inhibitor resistance in melanoma patients, accounting for about 60 to70 percent of patients. However, 30 to 40 percent of patients are relapsing by as yet uncovered mechanisms.

Going forward, Lo and his team will seek to find out what is happening molecularly in every patient that relapses after therapy, so novel combination drug strategies can be developed to help them. "If we know what happens in every relapse, we can have a plan in place that will help us avoid or overcome resistance," he said. About 70,000 new cases of melanoma are diagnosed each year in the United States. Of those, 8,000 people will die of the disease.


'/>"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles Health Sciences
Source:Eurekalert

Related medicine news :

1. No workout? No worries: Scientists prevent muscle loss in mice, despite disease and inactivity
2. New test can better predict successful IVF embryos, scientists say
3. NIH-supported scientists investigate a newly emerging staph strain
4. Scripps Florida scientists uncover inflammatory circuit that triggers breast cancer
5. UCLA scientists report link between traumatic brain injury, post-traumatic stress disorder
6. Scientists make strides toward fixing infant hearts
7. Scripps research scientists demonstrate effective new biopsy in a blood test to detect cancer
8. Scientists May Be Closer to Developing Red Wine Drug
9. Scientists Use Brain Waves to Eavesdrop on the Mind
10. Scripps research scientists illuminate cancer cells survival strategy
11. Scientists report first step in strategy for cell replacement therapy in Parkinsons disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... This month, the CEO and Clinical Director ... their drug rehab center in Delray Beach, Florida has been changed from Sober Living ... such as Philip Seymour Hoffman and Chris Farley are dying from heroin overdoses, but ...
(Date:1/19/2017)... ... January 19, 2017 , ... Cosmetic Town, an online plastic surgery community, begins ... make it easier for their readers to get the information they desire. The procedures ... as the techniques used on those particular areas. , “We are excited to streamline ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... provided a new $11,250,000 senior credit facility to Sunrise, Florida-based Management Health Systems, ... were used to facilitate a recapitalization of MedPro led by Harren Equity Partners. ...
(Date:1/19/2017)... CA (PRWEB) , ... January 19, 2017 , ... ... Health, is now offering treatments for patients with sleep apnea and TMJ disorders. ... for dental and physical health. Dr. Rassouli provides personalized care to reduce the ...
(Date:1/19/2017)... ... 19, 2017 , ... Sam & Associates Insurance Agency, a full service firm ... the California Bay Area, is launching a charity drive to raise awareness of heart ... is the primary killer of adult men and women in America, and is responsible ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... Research and Markets has announced the addition of the ... Opportunity Analysis and Industry Forecast, 2014-2022" report to their offering. ... Vital signs monitoring market size ... million by 2022, growing at a CAGR of 5.8% from 2016 to ... leading regional market in global vital signs monitoring devices industry. The blood ...
(Date:1/18/2017)... -- Adaptive Sound Technologies, Inc. (ASTI), the leading supplier of ... Place Nashville/Downtown to deliver the best sleep experience for ... in over two hundred of its guest rooms. ... having a great stay is sleeping well," said ... "We,re pleased to be able to offer our guests ...
(Date:1/18/2017)... FALLS, N.J. , Jan. 18, 2017   ... ), a biotechnology company specializing in the development and ... of damaged tissues and organs, recently reported the Company,s ... milestones for 2017. As the Company described ... has been a year of substantial accomplishments. The Company,s ...
Breaking Medicine Technology: